NASDAQ:AGEN - Agenus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 562.65 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.66
▲ +0.08 (5.06%)

This chart shows the closing price for AGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Agenus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGEN

Analyst Price Target is $11.00
▲ +562.65% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Agenus in the last 3 months. The average price target is $11.00, with a high forecast of $14.00 and a low forecast of $8.00. The average price target represents a 562.65% upside from the last price of $1.66.

This chart shows the closing price for AGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Agenus. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/3/2022B. RileyLower Price Target$11.00 ➝ $8.00Medium
3/2/2022HC WainwrightBoost Price TargetBuy$12.00 ➝ $14.00High
12/16/2021HC WainwrightInitiated CoverageBuy$12.00High
10/25/2021B. RileyReiterated RatingBuy$12.00 ➝ $11.00High
9/7/2021B. RileyBoost Price TargetBuy$11.00 ➝ $12.00High
1/15/2021B. RileyReiterated RatingBuy$8.00High
12/10/2020B. RileyReiterated RatingBuy$8.00Medium
9/23/2020William BlairReiterated RatingBuyLow
9/18/2020Jefferies Financial GroupBoost Price TargetBuy$5.00 ➝ $8.00Medium
6/22/2020B. RileyReiterated RatingBuy$6.00Low
6/5/2020B. RileyReiterated RatingBuy$6.00Low
5/29/2020B. RileyReiterated RatingBuy$6.00High
5/22/2020B. RileyReiterated RatingBuy$6.00Low
12/20/2019B. RileyInitiated CoverageBuy$6.00High
11/19/2019B. RileyInitiated CoverageBuy$6.00Low
4/22/2019B. RileyInitiated CoverageBuy ➝ Buy$5.00 ➝ $5.00Medium
8/4/2017Jefferies Financial GroupReiterated RatingBuy$7.00High
(Data available from 5/17/2017 forward)

News Sentiment Rating

-0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/19/2021
  • 4 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 4 very negative mentions
11/18/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2021
  • 0 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/17/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
3/18/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2022
  • 0 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
5/17/2022

Current Sentiment

  • 0 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Agenus logo
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $1.66
Low: $1.58
High: $1.66

50 Day Range

MA: $2.33
Low: $1.51
High: $3.11

52 Week Range

Now: $1.66
Low: $1.48
High: $6.79

Volume

302,024 shs

Average Volume

4,568,902 shs

Market Capitalization

$449.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Agenus?

The following sell-side analysts have issued stock ratings on Agenus in the last twelve months: B. Riley, HC Wainwright, StockNews.com, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for AGEN.

What is the current price target for Agenus?

2 Wall Street analysts have set twelve-month price targets for Agenus in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 572.8%. HC Wainwright has the highest price target set, predicting AGEN will reach $14.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $8.00 for Agenus in the next year.
View the latest price targets for AGEN.

What is the current consensus analyst rating for Agenus?

Agenus currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGEN will outperform the market and that investors should add to their positions of Agenus.
View the latest ratings for AGEN.

How do I contact Agenus' investor relations team?

Agenus' physical mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (781) 674-4400 and its investor relations email address is [email protected] The official website for Agenus is agenusbio.com. Learn More about contacing Agenus investor relations.